Caboxen 20 MG And 80 MG (Cabozantinib)

Basic Product Information of Caboxen 20 MG & 80 MG (Cabozantinib)

How Caboxen 20 MG & 80 MG Works Multi-Receptor Tyrosine Kinase Inhibition Mechanism

Cabozantinib, the active ingredient in Caboxen 20 MG and 80 MG, is a small-molecule, multi-receptor tyrosine kinase inhibitor (TKI) with potent inhibitory activity against a broad panel of receptor tyrosine kinases (RTKs) central to tumour angiogenesis, growth, survival, and metastatic dissemination. Cabozantinib’s primary molecular targets include Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), Hepatocyte Growth Factor Receptor (MET), and AXL receptor tyrosine kinase, in addition to RET, KIT, TYRO3, MER, TIE2, FLT3, and TRKB. By simultaneously suppressing these interconnected oncogenic and angiogenic signalling pathways, Cabozantinib produces a multi-dimensional anti-tumour effect that single-target VEGFR inhibitors cannot replicate. Solid tumours most susceptible to cabozantinib including renal cell carcinoma (RCC), medullary thyroid cancer (MTC), and hepatocellular carcinoma (HCC) are characterised by pathological co-activation of VEGFR, MET, and AXL, which drives angiogenesis, invasion, and resistance to prior targeted therapies.

Cabozantinib’s mechanistic advantage over first-generation VEGFR-targeting agents such as sunitinib and sorafenib derives from its ability to block the MET-driven compensatory escape mechanism the primary molecular pathway by which tumours overcome VEGFR2 suppression and acquire resistance to anti-angiogenic monotherapy. When VEGFR2 is blocked, HGF/MET signalling is upregulated as a tumour survival mechanism, restoring angiogenesis and promoting invasive growth; cabozantinib blocks both axes simultaneously, preventing this escape. AXL inhibition confers an additional benefit by suppressing immune evasion AXL activation on tumour cells and tumour-associated macrophages reduces NK cell activity and CD8+ T-cell infiltration within the tumour microenvironment, and AXL blockade by cabozantinib restores innate and adaptive anti-tumour immune surveillance. Mediaid Pharmacy’s oncology medicines catalogue includes a broad range of targeted kinase inhibitors and precision oncology agents used alongside cabozantinib in comprehensive solid tumour management.

In the landmark EXAM trial in progressive metastatic medullary thyroid cancer, cabozantinib delivered a median progression-free survival (PFS) of 11.2 months versus 4.0 months for placebo a hazard ratio of 0.28 representing a 72% reduction in disease progression risk. In the METEOR trial in advanced renal cell carcinoma following prior antiangiogenic therapy, cabozantinib achieved a median overall survival (OS) of 21.4 months versus 16.5 months for everolimus, with a median PFS of 7.4 months versus 3.8 months establishing cabozantinib as the benchmark second-line RCC agent. In the CABOSUN trial in intermediate- and poor-risk treatment-naïve advanced RCC, cabozantinib demonstrated a median PFS of 8.6 months versus 5.3 months for sunitinib (HR 0.48), establishing first-line superiority over the prior standard-of-care VEGFR TKI in this population.

Approved Indications for Caboxen 20 MG & 80 MG (Cabozantinib)

Caboxen 20 MG and 80 MG (Cabozantinib) is indicated across three distinct solid tumour settings where multi-kinase VEGFR/MET/AXL inhibition delivers clinically significant outcomes:

Key Clinical Benefits of Caboxen 20 MG & 80 MG (Cabozantinib)

How to Take Caboxen 20 MG & 80 MG (Cabozantinib) Dosage Guidelines

Clinical Monitoring Requirements During Caboxen (Cabozantinib) Treatment

Regular clinical monitoring is mandatory throughout Caboxen (Cabozantinib) treatment. Oncologists must monitor for gastrointestinal perforations and fistulae the most clinically critical serious adverse reaction, reported in approximately 3% of patients; Caboxen must be permanently discontinued if a perforation or Grade 4 fistula is confirmed. Severe haemorrhage including fatal pulmonary, gastrointestinal, and genitourinary haemorrhages was reported in approximately 3% of cabozantinib-treated patients in EXAM; permanent discontinuation is required for Grade 3 or higher haemorrhage. Arterial and venous thromboembolic events, including myocardial infarction, cerebrovascular accident, pulmonary embolism, and deep vein thrombosis, have been reported and require prompt evaluation and treatment interruption or discontinuation per severity. Hypertension should be monitored throughout treatment with blood pressure assessments before initiation and regularly during therapy; uncontrolled hypertension despite antihypertensive therapy requires dose reduction or temporary interruption. Hepatotoxicity including elevation of ALT, AST, and bilirubin requires liver function testing before initiation and periodically during treatment; hepatotoxicity Grade 3 or higher requires dose interruption and reduction upon recovery. Palmar-Plantar Erythrodysesthesia Syndrome (PPES), also known as hand-foot syndrome, is among the most common dose-limiting dermatological toxicities and should be actively monitored and managed with dose modification, urea-based emollients, and wound care as clinically indicated.

Drug Interactions and Important Safety Information for Caboxen (Cabozantinib)

Strong CYP3A4 inducers including rifampicin, carbamazepine, phenytoin, phenobarbital, St. John’s Wort (Hypericum perforatum), rifabutin, and rifapentine significantly reduce cabozantinib plasma exposure and must be avoided during Caboxen treatment wherever clinically possible, as they reduce cabozantinib area under the curve (AUC) by approximately 77%. When co-administration of a strong CYP3A4 inducer cannot be avoided, the Caboxen dose should be increased by 40 mg per day as described in dosing guidelines, and the prior dose resumed within 2–3 days of inducer discontinuation. Strong CYP3A4 inhibitors including ketoconazole, itraconazole, clarithromycin, ritonavir, and grapefruit/grapefruit juice increase cabozantinib plasma concentrations substantially and must be avoided or used with a corresponding dose reduction of 40 mg daily, with clinical vigilance for toxicity intensification.

Cabozantinib is a substrate and inhibitor of P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). Co-administration with P-gp or BCRP substrates with narrow therapeutic indices including digoxin, methotrexate, topotecan, and irinotecan may increase the plasma concentrations and toxicity risk of these agents; use the lowest effective doses and monitor closely. Cabozantinib may additionally potentiate the effects of anticoagulant agents including warfarin, as haemorrhagic risk is compounded by concurrent anticoagulation therapy; regular INR monitoring is essential if warfarin co-administration is clinically unavoidable. Patients must disclose all current medications, supplements, and herbal preparations to their oncologist before initiating Caboxen therapy.

Side Effects and Precautions of Caboxen 20 MG & 80 MG (Cabozantinib)

Who Should Use Caboxen 20 MG & 80 MG (Cabozantinib)?

Caboxen 20 MG and 80 MG (Cabozantinib) is indicated for adult patients across three oncology settings: adults with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC) with documented radiographic progression; adults with advanced renal cell carcinoma (RCC) either as first-line therapy in intermediate- or poor-risk patients or following prior antiangiogenic therapy; and adults with hepatocellular carcinoma (HCC) who have previously received sorafenib and have documented disease progression. Patients must have confirmed histological or cytological diagnosis and be assessed as having adequate hepatic function (Child-Pugh A or B), cardiac function, and blood pressure control before initiating Caboxen therapy. For MTC patients, assessment of RET mutation status is strongly recommended to inform prognosis and therapy sequencing, though RET mutation status is not a prerequisite for cabozantinib eligibility. Caboxen is prescribed exclusively by oncologists and endocrine oncology specialists with expertise in targeted therapy for solid tumours. A comprehensive baseline assessment including liver function tests, renal function, blood pressure, wound healing status, and dental evaluation is mandatory before commencing therapy. For patients requiring a complete portfolio of targeted oncology therapies including agents used in combination or sequentially with cabozantinib in RCC, HCC, and thyroid cancer management Mediaid Pharmacy’s oncology specialty medicines portfolio provides a comprehensive range of precision cancer treatments sourced from verified international manufacturers.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Caboxen 20 MG & 80 MG (Cabozantinib)

Mediaid Pharmacy is a trusted global supplier of specialty oncology and targeted therapy medications. Caboxen 20 MG and 80 MG (Cabozantinib) is available through Mediaid Pharmacy with reliable worldwide shipping to South Asia, the Middle East, Africa, Southeast Asia, Europe, and beyond. Our specialist team provides complete order support including pricing quotations, stock availability confirmation, regulatory and import documentation, and end-to-end international delivery tracking. Contact Mediaid Pharmacy directly via WhatsApp, phone, or WeChat for all enquiries regarding Caboxen (Cabozantinib) availability, pack size options (30’s and 90’s), pricing, and international delivery to your country.

Why Choose Caboxen 20 MG & 80 MG (Cabozantinib) from Mediaid Pharmacy?

Caboxen 20 MG and 80 MG represents a clinically proven and globally accessible cabozantinib formulation for patients with progressive MTC, advanced RCC, and previously treated HCC the three solid malignancies for which cabozantinib has demonstrated statistically significant survival benefit in phase III randomised trials. The availability of both the 20 MG and 80 MG capsule strengths is a critical pharmacological necessity: together, they enable oncologists to administer the full standard 140 mg starting dose (one 80 mg + three 20 mg capsules) and execute the two-step dose reduction protocol to 100 mg (one 80 mg + one 20 mg) and 60 mg (three 20 mg) with precision, without tablet manipulation or splitting. Supplied in 30-capsule and 90-capsule pack sizes, Caboxen accommodates both monthly dispensing cycles and longer-supply prescriptions, supporting continuity of therapy for patients maintained on chronic cabozantinib dosing across all approved indications. Distributed globally by Mediaid Pharmacy with worldwide shipping, Caboxen gives patients and oncology teams in both developed and emerging healthcare markets access to fully validated cabozantinib multi-kinase inhibitor therapy. For patients and oncologists requiring a comprehensive range of targeted solid tumour and oncology medicines, Mediaid Pharmacy’s oncology medicines section provides a complete portfolio of specialty cancer treatments sourced from verified manufacturers. For any patient or oncologist seeking a proven, accessible, and precisely dosed cabozantinib option, Caboxen 20 MG and 80 MG from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Caboxen 20 MG & 80 MG (Cabozantinib)